5. The compound of claim 1 wherein R^1 and R^3 are hydrogen, R^2 is hydrogen, fluoro, or trifluoromethyl;
R^4 is methyl or difluoromethyl;
X^1 is CH or CF;
X^2, X^3, and X^4 are CH;
L is -NHCO-;
Ar is 5-chloropyridin-2-yl, 5-cyanopyridin-2-yl, 5-fluoropyridin-2-yl, 5-cyano-3-fluorooropyridin-2-yl, 5-methoxypyrazin-2-yl or 1-difluoromethylpyrazol-3-yl; or an addition salt or a solvate thereof.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in any one of claims 1 to 5 and a pharmaceutically acceptable carrier.

7. A process for preparing a pharmaceutical composition as defined in claim 6, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in any one of claims 1 to 5.

8. A compound as defined in any one of claims 1 to 5 for use in the treatment or prevention of Alzheimer's disease, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

9. Use of a compound as defined in any one of claims 1 to 5 or a pharmaceutical composition as defined in claim 6 in the manufacture of a medicament for the treatment of ~~A method of treating~~ a disorder selected from the group consisting of Alzheimer's disease, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta-amyloid~~, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound as defined in any one of claims 1 to 5 or a pharmaceutical composition as defined in claim 6~~.